[
    {
        "pregunta": "1. What are the first-line therapies recommended for gout flares according to the 2020 American College of Rheumatology Guideline?",
        "respuesta": "The first-line therapies recommended for gout flares according to the 2020 American College of Rheumatology Guideline are oral colchicine, NSAIDs, or glucocorticoids (oral, intraarticular, or intramuscular). It is strongly recommended to use these therapies as appropriate first-line therapy for gout flares over IL-1 inhibitors or ACTH. Additionally, when colchicine is chosen, low-dose colchicine is strongly recommended over high-dose colchicine due to similar efficacy and fewer adverse effects. ",
        "contexto": [
            "access to an effective oral medication, the Patient Panel also indicated its preference for an injectable therapy in appropriate circumstances to achieve pain relief as quickly as possible (for all recommendations for gout flare managment, see Table 6 4 http://online library.wiley.com/doi/10.1002/acr.24180/abstract Management of lifestyle factors Limiting alcohol intake is conditionally recommended for patients with gout, regardless of disease activity. Limiting purine intake is conditionally recommended for patients with gout, regardless of disease activity. Limiting high-fructose corn syrup intake is conditionally recommended for patients with gout, regardless of disease activity. Using a weight loss program (no specific program endorsed) is conditionally recommended for those patients with gout who are overweight/ obese, regardless of disease activity. Certainty of evidence For patients experiencing a gout flare, we strongly recommend using oral colchicine, NSAIDs, or",
            "and not meant to be pursued at \"any cost.\" Even strong recommendations require sound clinical judgment to balance the potential clinical benefits and harms (including costs) of medical decisions Gout flare management Using colchicine, NSAIDs, or glucocorticoids (oral, intraarticular, or intramuscular) as appropriate firstline therapy for gout flares over IL-1 inhibitors or adrenocorticotropic hormone (ACTH) is strongly recommended for patients experiencing a gout flare. Given similar efficacy and a lower risk of adverse effects, low-dose colchicine over high-dose colchicine is strongly recommended when colchicine is the chosen agent. † There is moderate certainty of evidence about the efficacy of the benefits, harms, and high certainty about the costs of pegloticase. For patients with high disease activity, the magnitude of potential benefits outweighs the harms and costs of the drug. ‡ For patients with minimal disease activity, the smaller potential benefits do not outweigh the",
            "<p>|Recommendation|PICO question|Certainty of evidence|\n|---|---|---|\n|For patients experiencing a gout flare, we strongly recommend using oral colchicine, NSAIDs, or glucocorticoids (oral, intraarticular, or intramuscular) as appropriate first-line therapy for gout flares over IL-1 inhibitors or ACTH (the choice of colchicine, NSAIDs, or glucocorticoids should be made based on patient factors and preferences).|32|High†|\n|When colchicine is the chosen agent, we strongly recommend low-dose colchicine over high-dose colchicine given its similar efficacy and fewer adverse effects.| | |\n|For patients experiencing a gout flare for whom other antiinflammatory therapies are poorly tolerated or contraindicated, we conditionally recommend using IL-1 inhibition over no therapy (beyond supportive/analgesic treatment).|33|Moderate|\n|For patients who may receive NPO, we strongly recommend glucocorticoids (intramuscular, intravenous, or intraarticular) over IL-1 inhibitors or ACTH.|32|High†|",
            "regardless of disease activity. Certainty of evidence For patients experiencing a gout flare, we strongly recommend using oral colchicine, NSAIDs, or glucocorticoids (oral, intraarticular, or intramuscular) as appropriate first-line therapy for gout flares over IL-1 inhibitors or ACTH (the choice of colchicine, NSAIDs, or glucocorticoids should be made based on patient factors and preferences). When colchicine is the chosen agent, we strongly recommend low-dose colchicine over high-dose colchicine given its similar efficacy and fewer adverse effects. High † For patients experiencing a gout flare for whom other antiinflammatory therapies are poorly tolerated or contraindicated, we conditionally recommend using IL-1 inhibition over no therapy (beyond supportive/ analgesic treatment). Moderate For patients who may receive NPO, we strongly recommend glucocorticoids (intramuscular, intravenous, or intraarticular) over IL-1 inhibitors or ACTH. High † For patients experiencing a gout flare,",
            "|We strongly recommend initiating concomitant antiinflammatory prophylaxis therapy (e.g., colchicine, NSAIDs, prednisone/prednisolone) over no antiinflammatory prophylaxis.|9|Moderate|\n|The choice of specific antiinflammatory prophylaxis should be based upon patient factors.| | |\n|We strongly recommend continuing prophylaxis for 3–6 months rather than &lt;3 months, with ongoing evaluation and continued prophylaxis as needed if the patient continues to experience flares.|9|Moderate|\n|When the decision is made that ULT is indicated while the patient is experiencing a gout flare, we conditionally recommend starting ULT during the gout flare over starting ULT after the gout flare has resolved.|6|Moderate|\n|We strongly recommend against pegloticase as first-line therapy.|10|Moderate†|</p>"
        ]
    },
    {
        "pregunta": "2. How is the choice between colchicine, NSAIDs, and glucocorticoids determined in the management of gout flares?",
        "respuesta": "The choice between colchicine, NSAIDs, and glucocorticoids in the management of gout flares should be determined based on patient factors and preferences. The 2020 American College of Rheumatology Guideline strongly recommends using oral colchicine, NSAIDs, or glucocorticoids as appropriate first-line therapy for gout flares over IL-1 inhibitors or ACTH. When colchicine is chosen, low-dose colchicine is recommended over high-dose colchicine due to similar efficacy and fewer adverse effects. It is important to consider the patient's individual situation and choose the most suitable medication based on their specific needs.",
        "contexto": [
            "regardless of disease activity. Certainty of evidence For patients experiencing a gout flare, we strongly recommend using oral colchicine, NSAIDs, or glucocorticoids (oral, intraarticular, or intramuscular) as appropriate first-line therapy for gout flares over IL-1 inhibitors or ACTH (the choice of colchicine, NSAIDs, or glucocorticoids should be made based on patient factors and preferences). When colchicine is the chosen agent, we strongly recommend low-dose colchicine over high-dose colchicine given its similar efficacy and fewer adverse effects. High † For patients experiencing a gout flare for whom other antiinflammatory therapies are poorly tolerated or contraindicated, we conditionally recommend using IL-1 inhibition over no therapy (beyond supportive/ analgesic treatment). Moderate For patients who may receive NPO, we strongly recommend glucocorticoids (intramuscular, intravenous, or intraarticular) over IL-1 inhibitors or ACTH. High † For patients experiencing a gout flare,",
            "and not meant to be pursued at \"any cost.\" Even strong recommendations require sound clinical judgment to balance the potential clinical benefits and harms (including costs) of medical decisions Gout flare management Using colchicine, NSAIDs, or glucocorticoids (oral, intraarticular, or intramuscular) as appropriate firstline therapy for gout flares over IL-1 inhibitors or adrenocorticotropic hormone (ACTH) is strongly recommended for patients experiencing a gout flare. Given similar efficacy and a lower risk of adverse effects, low-dose colchicine over high-dose colchicine is strongly recommended when colchicine is the chosen agent. † There is moderate certainty of evidence about the efficacy of the benefits, harms, and high certainty about the costs of pegloticase. For patients with high disease activity, the magnitude of potential benefits outweighs the harms and costs of the drug. ‡ For patients with minimal disease activity, the smaller potential benefits do not outweigh the",
            "<p>|Recommendation|PICO question|Certainty of evidence|\n|---|---|---|\n|For patients experiencing a gout flare, we strongly recommend using oral colchicine, NSAIDs, or glucocorticoids (oral, intraarticular, or intramuscular) as appropriate first-line therapy for gout flares over IL-1 inhibitors or ACTH (the choice of colchicine, NSAIDs, or glucocorticoids should be made based on patient factors and preferences).|32|High†|\n|When colchicine is the chosen agent, we strongly recommend low-dose colchicine over high-dose colchicine given its similar efficacy and fewer adverse effects.| | |\n|For patients experiencing a gout flare for whom other antiinflammatory therapies are poorly tolerated or contraindicated, we conditionally recommend using IL-1 inhibition over no therapy (beyond supportive/analgesic treatment).|33|Moderate|\n|For patients who may receive NPO, we strongly recommend glucocorticoids (intramuscular, intravenous, or intraarticular) over IL-1 inhibitors or ACTH.|32|High†|",
            "benefits outweighs the harms and costs of the drug. ‡ For patients with minimal disease activity, the smaller potential benefits do not outweigh the harms and costs of the drug. Using topical ice as an adjuvant treatment over no adjuvant treatment is conditionally recommended for patients experiencing a gout flare. Using an IL-1 inhibitor over no therapy (beyond supportive/analgesic treatment) is conditionally recommended for patients experiencing a gout flare for whom the above antiinflammatory therapies are either ineffective, poorly tolerated, or contraindicated. Treatment with glucocorticoids (intramuscular, intravenous, or intraarticular) over IL-1 inhibitors or ACTH is strongly recommended for patients who are unable to take oral medications. The Voting Panel's recommendation of colchicine, NSAIDs, or glucocorticoids as preferred first-line therapies was based on substantial trial data demonstrating efficacy, relative low cost (versus IL-1 inhibitors and ACTH), and tolerability",
            "NSAIDs, prednisone/prednisolone) over no antiinflammatory prophylaxis. The choice of specific antiinflammatory prophylaxis should be based upon patient factors. Moderate We strongly recommend continuing prophylaxis for 3-6 months rather than <3 months, with ongoing evaluation and continued prophylaxis as needed if the patient continues to experience flares. Moderate When the decision is made that ULT is indicated while the patient is experiencing a gout flare, we conditionally recommend starting ULT during the gout flare over starting ULT after the gout flare has resolved. Moderate We strongly recommend against pegloticase as first-line therapy. 10 Moderate † * PICO = population, intervention, comparator, outcomes; CKD = chronic kidney disease; NSAIDs = nonsteroidal antiinflammatory drugs. † Moderate evidence is in support of the efficacy of pegloticase, but due to cost, safety concerns, and favorable benefit-to-harm ratios of other untried treatment options, the recommendation is"
        ]
    },
    {
        "pregunta": "3. What is the recommendation for using IL-1 inhibitors in patients with gout flares who cannot tolerate other anti-inflammatory therapies?",
        "respuesta": "The recommendation for using IL-1 inhibitors in patients with gout flares who cannot tolerate other anti-inflammatory therapies is to conditionally recommend using IL-1 inhibition over no therapy (beyond supportive/analgesic treatment). This recommendation is based on moderate certainty of evidence. It is important to consult with a healthcare provider for personalized treatment options in this scenario.",
        "contexto": [
            "<p>|Recommendation|PICO question|Certainty of evidence|\n|---|---|---|\n|For patients experiencing a gout flare, we strongly recommend using oral colchicine, NSAIDs, or glucocorticoids (oral, intraarticular, or intramuscular) as appropriate first-line therapy for gout flares over IL-1 inhibitors or ACTH (the choice of colchicine, NSAIDs, or glucocorticoids should be made based on patient factors and preferences).|32|High†|\n|When colchicine is the chosen agent, we strongly recommend low-dose colchicine over high-dose colchicine given its similar efficacy and fewer adverse effects.| | |\n|For patients experiencing a gout flare for whom other antiinflammatory therapies are poorly tolerated or contraindicated, we conditionally recommend using IL-1 inhibition over no therapy (beyond supportive/analgesic treatment).|33|Moderate|\n|For patients who may receive NPO, we strongly recommend glucocorticoids (intramuscular, intravenous, or intraarticular) over IL-1 inhibitors or ACTH.|32|High†|",
            "benefits outweighs the harms and costs of the drug. ‡ For patients with minimal disease activity, the smaller potential benefits do not outweigh the harms and costs of the drug. Using topical ice as an adjuvant treatment over no adjuvant treatment is conditionally recommended for patients experiencing a gout flare. Using an IL-1 inhibitor over no therapy (beyond supportive/analgesic treatment) is conditionally recommended for patients experiencing a gout flare for whom the above antiinflammatory therapies are either ineffective, poorly tolerated, or contraindicated. Treatment with glucocorticoids (intramuscular, intravenous, or intraarticular) over IL-1 inhibitors or ACTH is strongly recommended for patients who are unable to take oral medications. The Voting Panel's recommendation of colchicine, NSAIDs, or glucocorticoids as preferred first-line therapies was based on substantial trial data demonstrating efficacy, relative low cost (versus IL-1 inhibitors and ACTH), and tolerability",
            "regardless of disease activity. Certainty of evidence For patients experiencing a gout flare, we strongly recommend using oral colchicine, NSAIDs, or glucocorticoids (oral, intraarticular, or intramuscular) as appropriate first-line therapy for gout flares over IL-1 inhibitors or ACTH (the choice of colchicine, NSAIDs, or glucocorticoids should be made based on patient factors and preferences). When colchicine is the chosen agent, we strongly recommend low-dose colchicine over high-dose colchicine given its similar efficacy and fewer adverse effects. High † For patients experiencing a gout flare for whom other antiinflammatory therapies are poorly tolerated or contraindicated, we conditionally recommend using IL-1 inhibition over no therapy (beyond supportive/ analgesic treatment). Moderate For patients who may receive NPO, we strongly recommend glucocorticoids (intramuscular, intravenous, or intraarticular) over IL-1 inhibitors or ACTH. High † For patients experiencing a gout flare,",
            "over alternative agents when oral dosing is not possible. In patients experiencing an inadequate response to an initial agent, the Voting Panel cited insufficient evidence to make specific recommendations regarding subsequent antiinflammatory agents to use. If a patient is unable to tolerate or has contraindications to any of the other conventional alternatives, the Voting Panel conditionally recommended the use of IL-1 inhibitors , recognizing concerns over patient access due to cost. Noting limited supporting data Underscoring the importance of optimal flare management, the Patient Panel emphasized its preference for early intervention given the challenges of engaging a provider in timely manner, including an at-home \"medication-in-pocket\" strategy for patients who are able to identify the early signs of flare onset. In the absence of \"rapid\" access to an effective oral medication, the Patient Panel also indicated its preference for an injectable therapy in appropriate circumstances",
            "|We strongly recommend initiating concomitant antiinflammatory prophylaxis therapy (e.g., colchicine, NSAIDs, prednisone/prednisolone) over no antiinflammatory prophylaxis.|9|Moderate|\n|The choice of specific antiinflammatory prophylaxis should be based upon patient factors.| | |\n|We strongly recommend continuing prophylaxis for 3–6 months rather than &lt;3 months, with ongoing evaluation and continued prophylaxis as needed if the patient continues to experience flares.|9|Moderate|\n|When the decision is made that ULT is indicated while the patient is experiencing a gout flare, we conditionally recommend starting ULT during the gout flare over starting ULT after the gout flare has resolved.|6|Moderate|\n|We strongly recommend against pegloticase as first-line therapy.|10|Moderate†|</p>"
        ]
    },
    {
        "pregunta": "4. What is the preferred adjuvant treatment for gout flares, according to the guideline?",
        "respuesta": "The preferred adjuvant treatment for gout flares, based on the information provided, is the use of topical ice. It is conditionally recommended as an adjuvant treatment over no adjuvant treatment for patients experiencing a gout flare.",
        "contexto": [
            "|For patients experiencing a gout flare, we conditionally recommend using topical ice as an adjuvant treatment over no adjuvant treatment.|31|Low|</p>",
            "benefits outweighs the harms and costs of the drug. ‡ For patients with minimal disease activity, the smaller potential benefits do not outweigh the harms and costs of the drug. Using topical ice as an adjuvant treatment over no adjuvant treatment is conditionally recommended for patients experiencing a gout flare. Using an IL-1 inhibitor over no therapy (beyond supportive/analgesic treatment) is conditionally recommended for patients experiencing a gout flare for whom the above antiinflammatory therapies are either ineffective, poorly tolerated, or contraindicated. Treatment with glucocorticoids (intramuscular, intravenous, or intraarticular) over IL-1 inhibitors or ACTH is strongly recommended for patients who are unable to take oral medications. The Voting Panel's recommendation of colchicine, NSAIDs, or glucocorticoids as preferred first-line therapies was based on substantial trial data demonstrating efficacy, relative low cost (versus IL-1 inhibitors and ACTH), and tolerability",
            "NSAIDs, prednisone/prednisolone) over no antiinflammatory prophylaxis. The choice of specific antiinflammatory prophylaxis should be based upon patient factors. Moderate We strongly recommend continuing prophylaxis for 3-6 months rather than <3 months, with ongoing evaluation and continued prophylaxis as needed if the patient continues to experience flares. Moderate When the decision is made that ULT is indicated while the patient is experiencing a gout flare, we conditionally recommend starting ULT during the gout flare over starting ULT after the gout flare has resolved. Moderate We strongly recommend against pegloticase as first-line therapy. 10 Moderate † * PICO = population, intervention, comparator, outcomes; CKD = chronic kidney disease; NSAIDs = nonsteroidal antiinflammatory drugs. † Moderate evidence is in support of the efficacy of pegloticase, but due to cost, safety concerns, and favorable benefit-to-harm ratios of other untried treatment options, the recommendation is",
            "glucocorticoids (intramuscular, intravenous, or intraarticular) over IL-1 inhibitors or ACTH. High † For patients experiencing a gout flare, we conditionally recommend using topical ice as an adjuvant treatment over no adjuvant treatment. Low * PICO = population, intervention, comparator, outcomes; NSAIDs = nonsteroidal antiinflammatory drugs; IL-1 = interleukin-1; ACTH = adrenocorticotropic hormone; NPO = nothing by mouth (nulla per os). † High quality of evidence from network meta-analyses supporting canakinumab, which has superior mean pain score reduction and mean day-2 joint tenderness reduction. However, the Voting Panel raised concern that the comparator was weak (triamcinolone 40 mg) and that cost issues significantly favor other agents. Adding vitamin C supplementation is conditionally recommended against for patients with gout, regardless of disease activity. The Voting Panel discussed data demonstrating the important genetic contributions to the development and severity of",
            "|We strongly recommend initiating concomitant antiinflammatory prophylaxis therapy (e.g., colchicine, NSAIDs, prednisone/prednisolone) over no antiinflammatory prophylaxis.|9|Moderate|\n|The choice of specific antiinflammatory prophylaxis should be based upon patient factors.| | |\n|We strongly recommend continuing prophylaxis for 3–6 months rather than &lt;3 months, with ongoing evaluation and continued prophylaxis as needed if the patient continues to experience flares.|9|Moderate|\n|When the decision is made that ULT is indicated while the patient is experiencing a gout flare, we conditionally recommend starting ULT during the gout flare over starting ULT after the gout flare has resolved.|6|Moderate|\n|We strongly recommend against pegloticase as first-line therapy.|10|Moderate†|</p>"
        ]
    },
    {
        "pregunta": "5. What lifestyle factors are conditionally recommended to be limited in patients with gout?",
        "respuesta": "The lifestyle factors recommended to be limited in patients with gout are alcohol intake, purine intake, and high-fructose corn syrup intake. Additionally, weight loss is conditionally recommended for overweight or obese patients with gout. It is not recommended to add vitamin C supplementation for patients with gout.",
        "contexto": [
            "<h1>Table 7. Management of lifestyle factors*</h1>\n\n<p>|Recommendation|PICO|Certainty of evidence|\n|---|---|---|\n|For patients with gout, regardless of disease activity, we conditionally recommend limiting alcohol intake.|41|Low|\n|For patients with gout, regardless of disease activity, we conditionally recommend limiting purine intake.|42|Low|\n|For patients with gout, regardless of disease activity, we conditionally recommend limiting high-fructose corn syrup.|43|Very low|\n|For overweight/obese patients with gout, regardless of disease activity, we conditionally recommend weight loss.|46|Very low|\n|For patients with gout, regardless of disease activity, we conditionally recommend against adding vitamin C supplementation.|48|Low|</p>\n\n<ul>\n<li>PICO = population, intervention, comparator, outcomes.</li>\n</ul>\n\n<h1>Table 8. Management of concurrent medications*</h1>",
            "access to an effective oral medication, the Patient Panel also indicated its preference for an injectable therapy in appropriate circumstances to achieve pain relief as quickly as possible (for all recommendations for gout flare managment, see Table 6 4 http://online library.wiley.com/doi/10.1002/acr.24180/abstract Management of lifestyle factors Limiting alcohol intake is conditionally recommended for patients with gout, regardless of disease activity. Limiting purine intake is conditionally recommended for patients with gout, regardless of disease activity. Limiting high-fructose corn syrup intake is conditionally recommended for patients with gout, regardless of disease activity. Using a weight loss program (no specific program endorsed) is conditionally recommended for those patients with gout who are overweight/ obese, regardless of disease activity. Certainty of evidence For patients experiencing a gout flare, we strongly recommend using oral colchicine, NSAIDs, or",
            "regardless of disease activity. The Voting Panel discussed data demonstrating the important genetic contributions to the development and severity of hyperuricemia and gout 7 5 http://onlinelibrary.wiley.com/doi/10.1002/acr.24180/abstract Alcohol. SU levels among patients who limited or abstained from alcohol were 1.6 mg/dl lower compared with patients who did not do so In a case-crossover study, consuming >1-2 alcoholic beverage servings in the prior 24 hours was associated with a 40% higher risk of gout flare than periods without alcohol consumption, with a dose-response relationship Low purine diet. From the same case-crossover study noted above, there was a dose-response relationship between increasing purine intake and risk of gout flare High-fructose corn syrup. The ingestion of 1 gm of fructose/kg of body weight increases SU concentration by 1-2 mg/dl within 2 hours of ingestion Weight loss. The Voting Panel considered the impact of weight loss and specific dietary programs",
            "medications that might affect SU levels, and for which the Patient Panel requested guidance. The Voting Panel aimed to provide guidance without implying any \"patient-blaming\" for the manifestations of gout given its strong genetic determinants. Indications for ULT are expanded from the 2012 ACR Guidelines for the Management of Gout, but consistent with the 2016 update of the EULAR gout recommendations This updated guideline effort also identifies several areas that inform a research agenda for gout management. While data support an active treat-to-target strategy, a question remains as to what may be the optimal SU threshold for patients with more severe disease, in addition to questions about threshold values in specific populations of gout patients. Gout has differential impact on patients by sex, race, or by presence of other comorbidities. This guideline is limited in commenting on specific groups of gout patients, as more studies of specific patient cohorts are needed in order to",
            "guidelines do not directly address the impact of gout or hyperuricemia on other comorbidities, such as cardiovascular disease (CVD), hypertension, urolithiasis, or chronic kidney disease (CKD). As we developed these guidelines for use by providers practicing in the US, we considered pharmacologic therapies available in the US, with select exceptions. Although lesinurad was withdrawn from the US market by the manufacturer during the course of guideline development, it remains Food and Drug Administration (FDA) approved, and we therefore considered the data in relation to relevant PICO questions. To facilitate the 2 NMAs, we also considered medications not available in the US to permit comparisons with other available medications in the network analysis. | 747 RESULTS/RECOMMENDATIONS Indications for pharmacologic ULT Initiating ULT is strongly recommended for gout patients with any of the following: ≥1 subcutaneous tophi; evidence of radiographic damage (any modality) attributable to"
        ]
    },
    {
        "pregunta": "6. What is the recommendation regarding the use of vitamin C supplementation in patients with gout?",
        "respuesta": "The recommendation regarding the use of vitamin C supplementation in patients with gout is to conditionally recommend against adding vitamin C supplementation. This recommendation is based on low certainty of evidence.",
        "contexto": [
            "<h1>Table 7. Management of lifestyle factors*</h1>\n\n<p>|Recommendation|PICO|Certainty of evidence|\n|---|---|---|\n|For patients with gout, regardless of disease activity, we conditionally recommend limiting alcohol intake.|41|Low|\n|For patients with gout, regardless of disease activity, we conditionally recommend limiting purine intake.|42|Low|\n|For patients with gout, regardless of disease activity, we conditionally recommend limiting high-fructose corn syrup.|43|Very low|\n|For overweight/obese patients with gout, regardless of disease activity, we conditionally recommend weight loss.|46|Very low|\n|For patients with gout, regardless of disease activity, we conditionally recommend against adding vitamin C supplementation.|48|Low|</p>\n\n<ul>\n<li>PICO = population, intervention, comparator, outcomes.</li>\n</ul>\n\n<h1>Table 8. Management of concurrent medications*</h1>",
            "or high certainty of evidence where the benefits consistently outweigh the risks, and, with only rare exceptions, an informed patient and his or her provider would be expected to reach the same decision. Conditional recommendations reflect scenarios for which the benefits and risks may be more closely balanced and/or only low certainty of evidence or no data are available. Recommendations in this guideline apply to patients with gout, except for a single recommendation regarding the use of ULT in individuals with asymptomatic hyperuricemia, which is defined as an SU concentration of ≥6.8 mg/dl with no prior gout flares or subcutaneous tophi. Patients with evidence of monosodium urate monohydrate (MSU) deposition on advanced imaging may still be considered asymptomatic if they have not had a prior gout flare or subcutaneous tophi. These guidelines do not directly address the impact of gout or hyperuricemia on other comorbidities, such as cardiovascular disease (CVD), hypertension,",
            "access to an effective oral medication, the Patient Panel also indicated its preference for an injectable therapy in appropriate circumstances to achieve pain relief as quickly as possible (for all recommendations for gout flare managment, see Table 6 4 http://online library.wiley.com/doi/10.1002/acr.24180/abstract Management of lifestyle factors Limiting alcohol intake is conditionally recommended for patients with gout, regardless of disease activity. Limiting purine intake is conditionally recommended for patients with gout, regardless of disease activity. Limiting high-fructose corn syrup intake is conditionally recommended for patients with gout, regardless of disease activity. Using a weight loss program (no specific program endorsed) is conditionally recommended for those patients with gout who are overweight/ obese, regardless of disease activity. Certainty of evidence For patients experiencing a gout flare, we strongly recommend using oral colchicine, NSAIDs, or",
            "|For patients with asymptomatic hyperuricemia (SU &gt;6.8 mg/dl with no prior gout flares or subcutaneous tophi), we conditionally recommend against initiating any pharmacologic ULT (allopurinol, febuxostat, probenecid) over initiation of pharmacologic ULT.|57|High†|</p>",
            "<p>|Recommendation|PICO question|Certainty of evidence|\n|---|---|---|\n|For patients experiencing a gout flare, we strongly recommend using oral colchicine, NSAIDs, or glucocorticoids (oral, intraarticular, or intramuscular) as appropriate first-line therapy for gout flares over IL-1 inhibitors or ACTH (the choice of colchicine, NSAIDs, or glucocorticoids should be made based on patient factors and preferences).|32|High†|\n|When colchicine is the chosen agent, we strongly recommend low-dose colchicine over high-dose colchicine given its similar efficacy and fewer adverse effects.| | |\n|For patients experiencing a gout flare for whom other antiinflammatory therapies are poorly tolerated or contraindicated, we conditionally recommend using IL-1 inhibition over no therapy (beyond supportive/analgesic treatment).|33|Moderate|\n|For patients who may receive NPO, we strongly recommend glucocorticoids (intramuscular, intravenous, or intraarticular) over IL-1 inhibitors or ACTH.|32|High†|"
        ]
    },
    {
        "pregunta": "7. When should hydrochlorothiazide be switched to an alternate antihypertensive in patients with gout?",
        "respuesta": "Based on the retrieved documents, it is recommended to switch hydrochlorothiazide to an alternate antihypertensive when feasible for patients with gout, regardless of disease activity. This recommendation is based on very low certainty of evidence. If there are specific concerns or considerations regarding the use of hydrochlorothiazide in patients with gout, it is advisable to consult with a healthcare provider for personalized guidance on switching to an alternate antihypertensive.",
        "contexto": [
            "by 1-2 mg/dl within 2 hours of ingestion Weight loss. The Voting Panel considered the impact of weight loss and specific dietary programs (including the DASH diet Management of concurrent medications Switching hydrochlorothiazide to an alternate antihypertensive when feasible is conditionally recommended for patients with gout, regardless of disease activity. Choosing losartan preferentially as an antihypertensive agent when feasible is conditionally recommended for patients with gout, regardless of disease activity. Stopping low-dose aspirin (for patients taking this medication for appropriate indications) is conditionally recommended against for patients with gout, regardless of disease activity. Adding or switching cholesterol-lowering agents to fenofibrate is conditionally recommended against for patients with gout, regardless of disease activity. Medications noted above are known to have effects on SU concentrations Recognizing that there are few practical alternatives to lowdose",
            "<ul>\n<li>PICO = population, intervention, comparator, outcomes.</li>\n</ul>\n\n<h1>Table 8. Management of concurrent medications*</h1>\n\n<p>|Recommendation|PICO question|Certainty of evidence|\n|---|---|---|\n|For patients with gout, regardless of disease activity, we conditionally recommend switching hydrochlorothiazide to an alternate antihypertensive when feasible.|47|Very low|\n|We conditionally recommend choosing losartan preferentially as an antihypertensive when feasible.|47|Very low|\n|We conditionally recommend against stopping low-dose aspirin (in those who are taking this medication for appropriate indications).|47|Very low|\n|We conditionally recommend against adding or switching to fenofibrate.|47|Very low|</p>\n\n<h2>* PICO = population, intervention, comparator, outcomes.</h2>",
            "who develop incident gout. However, based on the attributable risk, 24 patients would need to be treated for 3 years to prevent a single (incident) gout flare leading to the recommendation against initiating ULT in this patient group. Initiating ULT is conditionally recommended against in patients with asymptomatic hyperuricemia. For patients with asymptomatic hyperuricemia, RCTs (designed to study CVD outcomes) demonstrated significant reduction in incident gout flares over 3 years. However, the development of incident gout was low for both ULT and placebo arms (<1% versus 5%) Recommendations for choice of initial ULT for patients with gout Treatment with allopurinol as the preferred first-line agent, over all other ULTs, is strongly recommended for all patients, including those with moderate-to-severe CKD (stage ≥3). The Voting Panel strongly recommended allopurinol as the preferred first-line agent given its efficacy when dosed appropriately (often required doses >300 mg/day 2 2",
            "guidelines do not directly address the impact of gout or hyperuricemia on other comorbidities, such as cardiovascular disease (CVD), hypertension, urolithiasis, or chronic kidney disease (CKD). As we developed these guidelines for use by providers practicing in the US, we considered pharmacologic therapies available in the US, with select exceptions. Although lesinurad was withdrawn from the US market by the manufacturer during the course of guideline development, it remains Food and Drug Administration (FDA) approved, and we therefore considered the data in relation to relevant PICO questions. To facilitate the 2 NMAs, we also considered medications not available in the US to permit comparisons with other available medications in the network analysis. | 747 RESULTS/RECOMMENDATIONS Indications for pharmacologic ULT Initiating ULT is strongly recommended for gout patients with any of the following: ≥1 subcutaneous tophi; evidence of radiographic damage (any modality) attributable to",
            "NSAIDs, prednisone/prednisolone) over no antiinflammatory prophylaxis. The choice of specific antiinflammatory prophylaxis should be based upon patient factors. Moderate We strongly recommend continuing prophylaxis for 3-6 months rather than <3 months, with ongoing evaluation and continued prophylaxis as needed if the patient continues to experience flares. Moderate When the decision is made that ULT is indicated while the patient is experiencing a gout flare, we conditionally recommend starting ULT during the gout flare over starting ULT after the gout flare has resolved. Moderate We strongly recommend against pegloticase as first-line therapy. 10 Moderate † * PICO = population, intervention, comparator, outcomes; CKD = chronic kidney disease; NSAIDs = nonsteroidal antiinflammatory drugs. † Moderate evidence is in support of the efficacy of pegloticase, but due to cost, safety concerns, and favorable benefit-to-harm ratios of other untried treatment options, the recommendation is"
        ]
    },
    {
        "pregunta": "8. What is the recommended antihypertensive agent of choice for patients with gout?",
        "respuesta": "The recommended antihypertensive agent of choice for patients with gout, according to the retrieved documents, is to choose losartan preferentially as an antihypertensive agent when feasible. This recommendation is made for patients with gout, regardless of disease activity.",
        "contexto": [
            "by 1-2 mg/dl within 2 hours of ingestion Weight loss. The Voting Panel considered the impact of weight loss and specific dietary programs (including the DASH diet Management of concurrent medications Switching hydrochlorothiazide to an alternate antihypertensive when feasible is conditionally recommended for patients with gout, regardless of disease activity. Choosing losartan preferentially as an antihypertensive agent when feasible is conditionally recommended for patients with gout, regardless of disease activity. Stopping low-dose aspirin (for patients taking this medication for appropriate indications) is conditionally recommended against for patients with gout, regardless of disease activity. Adding or switching cholesterol-lowering agents to fenofibrate is conditionally recommended against for patients with gout, regardless of disease activity. Medications noted above are known to have effects on SU concentrations Recognizing that there are few practical alternatives to lowdose",
            "guidelines do not directly address the impact of gout or hyperuricemia on other comorbidities, such as cardiovascular disease (CVD), hypertension, urolithiasis, or chronic kidney disease (CKD). As we developed these guidelines for use by providers practicing in the US, we considered pharmacologic therapies available in the US, with select exceptions. Although lesinurad was withdrawn from the US market by the manufacturer during the course of guideline development, it remains Food and Drug Administration (FDA) approved, and we therefore considered the data in relation to relevant PICO questions. To facilitate the 2 NMAs, we also considered medications not available in the US to permit comparisons with other available medications in the network analysis. | 747 RESULTS/RECOMMENDATIONS Indications for pharmacologic ULT Initiating ULT is strongly recommended for gout patients with any of the following: ≥1 subcutaneous tophi; evidence of radiographic damage (any modality) attributable to",
            "access to an effective oral medication, the Patient Panel also indicated its preference for an injectable therapy in appropriate circumstances to achieve pain relief as quickly as possible (for all recommendations for gout flare managment, see Table 6 4 http://online library.wiley.com/doi/10.1002/acr.24180/abstract Management of lifestyle factors Limiting alcohol intake is conditionally recommended for patients with gout, regardless of disease activity. Limiting purine intake is conditionally recommended for patients with gout, regardless of disease activity. Limiting high-fructose corn syrup intake is conditionally recommended for patients with gout, regardless of disease activity. Using a weight loss program (no specific program endorsed) is conditionally recommended for those patients with gout who are overweight/ obese, regardless of disease activity. Certainty of evidence For patients experiencing a gout flare, we strongly recommend using oral colchicine, NSAIDs, or",
            "who develop incident gout. However, based on the attributable risk, 24 patients would need to be treated for 3 years to prevent a single (incident) gout flare leading to the recommendation against initiating ULT in this patient group. Initiating ULT is conditionally recommended against in patients with asymptomatic hyperuricemia. For patients with asymptomatic hyperuricemia, RCTs (designed to study CVD outcomes) demonstrated significant reduction in incident gout flares over 3 years. However, the development of incident gout was low for both ULT and placebo arms (<1% versus 5%) Recommendations for choice of initial ULT for patients with gout Treatment with allopurinol as the preferred first-line agent, over all other ULTs, is strongly recommended for all patients, including those with moderate-to-severe CKD (stage ≥3). The Voting Panel strongly recommended allopurinol as the preferred first-line agent given its efficacy when dosed appropriately (often required doses >300 mg/day 2 2",
            "<p><strong>Table 2. Recommendations for choice of initial urate-lowering therapy (ULT) in patients with gout*</strong>\n|Recommendation|PICO question|Certainty of evidence|\n|---|---|---|\n|For patients starting any ULT, we strongly recommend allopurinol over all other ULT as the preferred first-line agent for all patients, including in those with CKD stage &gt;3.|10|Moderate|\n|We strongly recommend a xanthine oxidase inhibitor over probenecid for those with CKD stage &gt;3.| | |\n|For allopurinol and febuxostat, we strongly recommend starting at a low dose with subsequent dose titration to target over starting at a higher dose (e.g., &lt;100 mg/day [and lower in patients with CKD] for allopurinol or &lt;40 mg/day for febuxostat).|7|Moderate|\n|For probenecid, we conditionally recommend starting at a low dose (500 mg once or twice daily) with dose titration over starting at a higher dose.| | |"
        ]
    },
    {
        "pregunta": "9. What is the recommendation regarding low-dose aspirin in patients with gout who are taking it for appropriate indications?",
        "respuesta": "I don't have specific information regarding the recommendation regarding low-dose aspirin in patients with gout who are taking it for appropriate indications.",
        "contexto": [
            "<h1>Table 7. Management of lifestyle factors*</h1>\n\n<p>|Recommendation|PICO|Certainty of evidence|\n|---|---|---|\n|For patients with gout, regardless of disease activity, we conditionally recommend limiting alcohol intake.|41|Low|\n|For patients with gout, regardless of disease activity, we conditionally recommend limiting purine intake.|42|Low|\n|For patients with gout, regardless of disease activity, we conditionally recommend limiting high-fructose corn syrup.|43|Very low|\n|For overweight/obese patients with gout, regardless of disease activity, we conditionally recommend weight loss.|46|Very low|\n|For patients with gout, regardless of disease activity, we conditionally recommend against adding vitamin C supplementation.|48|Low|</p>\n\n<ul>\n<li>PICO = population, intervention, comparator, outcomes.</li>\n</ul>\n\n<h1>Table 8. Management of concurrent medications*</h1>",
            "or high certainty of evidence where the benefits consistently outweigh the risks, and, with only rare exceptions, an informed patient and his or her provider would be expected to reach the same decision. Conditional recommendations reflect scenarios for which the benefits and risks may be more closely balanced and/or only low certainty of evidence or no data are available. Recommendations in this guideline apply to patients with gout, except for a single recommendation regarding the use of ULT in individuals with asymptomatic hyperuricemia, which is defined as an SU concentration of ≥6.8 mg/dl with no prior gout flares or subcutaneous tophi. Patients with evidence of monosodium urate monohydrate (MSU) deposition on advanced imaging may still be considered asymptomatic if they have not had a prior gout flare or subcutaneous tophi. These guidelines do not directly address the impact of gout or hyperuricemia on other comorbidities, such as cardiovascular disease (CVD), hypertension,",
            "with the maximum medically appropriate allopurinol dose (determined by the treating physician). For these patients with frequent gout flares or nonresolving subcutaneous tophi, clinical trials demonstrated improved SU concentrations, low frequency of flares The above scenarios represent extremes of gout clinical severity resulting in strong \"for\" and \"against\" recommendations. The Voting Panel considered intermediary scenarios, but given the potential variability, the panel opted to simply defer to provider judgment balanced with patient preferences, regarding the optimal treatment strategy for individuals not described above. To clarify, as outlined above, there is a strong recommendation to follow a treat-to-target management strategy for all patients receiving ULT. However, the recommendation for treat-to-target strategy is not absolute and not meant to be pursued at \"any cost.\" Even strong recommendations require sound clinical judgment to balance the potential clinical benefits",
            "guidelines do not directly address the impact of gout or hyperuricemia on other comorbidities, such as cardiovascular disease (CVD), hypertension, urolithiasis, or chronic kidney disease (CKD). As we developed these guidelines for use by providers practicing in the US, we considered pharmacologic therapies available in the US, with select exceptions. Although lesinurad was withdrawn from the US market by the manufacturer during the course of guideline development, it remains Food and Drug Administration (FDA) approved, and we therefore considered the data in relation to relevant PICO questions. To facilitate the 2 NMAs, we also considered medications not available in the US to permit comparisons with other available medications in the network analysis. | 747 RESULTS/RECOMMENDATIONS Indications for pharmacologic ULT Initiating ULT is strongly recommended for gout patients with any of the following: ≥1 subcutaneous tophi; evidence of radiographic damage (any modality) attributable to",
            "<p>|Recommendation|PICO question|Certainty of evidence|\n|---|---|---|\n|For patients experiencing a gout flare, we strongly recommend using oral colchicine, NSAIDs, or glucocorticoids (oral, intraarticular, or intramuscular) as appropriate first-line therapy for gout flares over IL-1 inhibitors or ACTH (the choice of colchicine, NSAIDs, or glucocorticoids should be made based on patient factors and preferences).|32|High†|\n|When colchicine is the chosen agent, we strongly recommend low-dose colchicine over high-dose colchicine given its similar efficacy and fewer adverse effects.| | |\n|For patients experiencing a gout flare for whom other antiinflammatory therapies are poorly tolerated or contraindicated, we conditionally recommend using IL-1 inhibition over no therapy (beyond supportive/analgesic treatment).|33|Moderate|\n|For patients who may receive NPO, we strongly recommend glucocorticoids (intramuscular, intravenous, or intraarticular) over IL-1 inhibitors or ACTH.|32|High†|"
        ]
    },
    {
        "pregunta": "10. What are the indications for initiating pharmacologic urate-lowering therapy (ULT) in patients with gout according to the guideline?",
        "respuesta": "Based on the retrieved guidelines, pharmacologic urate-lowering therapy (ULT) should be strongly recommended for patients with gout who have any of the following: ≥1 subcutaneous tophi or evidence of radiographic damage attributable to gout. It is also conditionally recommended against initiating ULT in patients with asymptomatic hyperuricemia. For patients with asymptomatic hyperuricemia, ULT has shown a significant reduction in incident gout flares over 3 years, but the development of incident gout was low for both ULT and placebo arms. It is important to consider these recommendations and consult with a healthcare provider for personalized treatment decisions in patients with gout.",
        "contexto": [
            "<h1>Table 1. Indications for pharmacologic urate-lowering therapy (ULT)*</h1>",
            "guidelines do not directly address the impact of gout or hyperuricemia on other comorbidities, such as cardiovascular disease (CVD), hypertension, urolithiasis, or chronic kidney disease (CKD). As we developed these guidelines for use by providers practicing in the US, we considered pharmacologic therapies available in the US, with select exceptions. Although lesinurad was withdrawn from the US market by the manufacturer during the course of guideline development, it remains Food and Drug Administration (FDA) approved, and we therefore considered the data in relation to relevant PICO questions. To facilitate the 2 NMAs, we also considered medications not available in the US to permit comparisons with other available medications in the network analysis. | 747 RESULTS/RECOMMENDATIONS Indications for pharmacologic ULT Initiating ULT is strongly recommended for gout patients with any of the following: ≥1 subcutaneous tophi; evidence of radiographic damage (any modality) attributable to",
            "who develop incident gout. However, based on the attributable risk, 24 patients would need to be treated for 3 years to prevent a single (incident) gout flare leading to the recommendation against initiating ULT in this patient group. Initiating ULT is conditionally recommended against in patients with asymptomatic hyperuricemia. For patients with asymptomatic hyperuricemia, RCTs (designed to study CVD outcomes) demonstrated significant reduction in incident gout flares over 3 years. However, the development of incident gout was low for both ULT and placebo arms (<1% versus 5%) Recommendations for choice of initial ULT for patients with gout Treatment with allopurinol as the preferred first-line agent, over all other ULTs, is strongly recommended for all patients, including those with moderate-to-severe CKD (stage ≥3). The Voting Panel strongly recommended allopurinol as the preferred first-line agent given its efficacy when dosed appropriately (often required doses >300 mg/day 2 2",
            "flares (<2/year), we conditionally recommend initiating ULT over no ULT. Moderate For patients experiencing their first flare, we conditionally recommend against initiating ULT over no ULT, with the following exceptions. Moderate For patients experiencing their first flare and CKD stage >3, SU >9 mg/dl, or urolithiasis, we conditionally recommend initiating ULT. Very low For patients with asymptomatic hyperuricemia (SU >6.8 mg/dl with no prior gout flares or subcutaneous tophi), we conditionally recommend against initiating any pharmacologic ULT (allopurinol, febuxostat, probenecid) over initiation of pharmacologic ULT. 57 High † * PICO = population, intervention, comparator, outcomes; CKD = chronic kidney disease; SU = serum urate. † There is randomized clinical trial data to support the benefit that ULT lowers the proportion of patients who develop incident gout. However, based on the attributable risk, 24 patients would need to be treated for 3 years to prevent a single (incident)",
            "<p><strong>Table 2. Recommendations for choice of initial urate-lowering therapy (ULT) in patients with gout*</strong>\n|Recommendation|PICO question|Certainty of evidence|\n|---|---|---|\n|For patients starting any ULT, we strongly recommend allopurinol over all other ULT as the preferred first-line agent for all patients, including in those with CKD stage &gt;3.|10|Moderate|\n|We strongly recommend a xanthine oxidase inhibitor over probenecid for those with CKD stage &gt;3.| | |\n|For allopurinol and febuxostat, we strongly recommend starting at a low dose with subsequent dose titration to target over starting at a higher dose (e.g., &lt;100 mg/day [and lower in patients with CKD] for allopurinol or &lt;40 mg/day for febuxostat).|7|Moderate|\n|For probenecid, we conditionally recommend starting at a low dose (500 mg once or twice daily) with dose titration over starting at a higher dose.| | |"
        ]
    }
]